Swiss perspectives in 10 languages

Switzerland builds stocks of anti-Covid treatments

GlaxoSmithKline logo
Switzerland has reserved 3,000 doses of GlaxoSmithKline's monoclonal antibody drug. Keystone / Laurent Gillieron

Switzerland has reserved 3,000 doses of the GlaxoSmithKline monoclonal sotrovimab drug to treat patients infected with Covid-19.

This adds to the 3,000 doses of a similar medicine, RegN-Cov 2, developed by Switzerland’s Roche and US biotech company Regeneron.

Monoclonal antibodies, which are cloned in culture and injected into patients, are seen as highly promising treatments to neutralise the virus, particularly in serious cases of infection. The antibody was discovered by Swiss company Humabs BioMed.

+ Read how the Institute of Research in Biomedicine (IRB) developed therapeutic uses for monoclonal antibodies with Humabs BioMed (well before Covid-19 was known)

Although the sotrovimab drug has yet to be granted regulatory approval in Switzerland, trials by GlaxoSmithKline show promising results, the government said in a press release on FridayExternal link.

The reservation of 3,000 doses of the drug was made on the recommendation of the Swiss National Covid-19 Taskforce.

The drug is intended as a treatment for at-risk patients who have an increased risk of severe infection.

More


News

Two Rothornbahn gondolas cross each other on Lenzerheide on Friday, April 3, 2009.

More

Swiss cable car activity rose in winter 2023-2024

This content was published on In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.

Read more: Swiss cable car activity rose in winter 2023-2024
flooding Rhine

More

Rhine flooding: Swiss to invest CHF1 billion with Austria

This content was published on As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.

Read more: Rhine flooding: Swiss to invest CHF1 billion with Austria

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR